title: Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke: determination of etiological, topographic, and radiological outcome factors.
abstract: OBJECTIVE
  Although new, large, double-blind, randomized studies are needed to establish the efficiency of intravenous thrombolysis, open trials of sufficient size may also provide novel data concerning specific outcomes after thrombolysis.
  
  
  METHODS
  An open study of intravenous rtPA in 100 patients with internal carotid artery (ICA) territory strokes between 20 and 81 years of age, with a baseline Scandinavian Stroke Scale (SSS) score of <48 at entry was conducted. Inclusion time was within 7 hours after stroke onset. rtPA (0.8 mg/kg) was infused for 90 minutes, with an initial 10% bolus. Heparin was given according to 3 consecutive protocols. The SSS evaluation was done on days 0, 1, 7, 30, and 90. CT scan was performed before treatment, on days 1 and 7. Etiological investigations included echocardiography and carotid Doppler sonography and/or angiography. Outcome at 1 year was documented by SSS score, the modified Rankin Scale (mRS) score, and a 10-point invalidity scale. Multivariate logistic regression was used to identify predictors of poor versus good outcome.
  
  
  RESULTS
  At day 90, 45 patients (45%) had a good result, defined as complete regression or slight neurological sequelae (mRS score of 0-1), 18 patients had a moderate outcome (mRS 2-3), and 31 patients had serious neurological sequelae (mRS 4-5). Six patients died, 2 with intracerebral hematoma after immediate heparin. Five of 11 patients (45.5%) treated between 6 and 7 hours had a good result. The overall intracerebral hematoma rate was 7%. Higher values of fibrin degradation products at 2 hours were observed in the subgroup with intracerebral hematomas. Significant predictors of poor outcome on multivariate logistic regression analysis were baseline SSS score of <15 (odds ratio [OR], 3.38; 95% confidence interval [CI], 1.07 to 10. 74; P=0.04), indistinction between white and gray matter on CT scan (OR, 6.59; 95% CI, 2.19 to 19.79; P=0.0008), and proximal internal carotid thrombosis (OR, 3.29; 95% CI, 0.99 to 10.95; P=0.05).
  
  
  CONCLUSIONS
  Our study confirms the safety of intravenous rtPA at a dose of 0.8 mg/kg and suggests efficacy for this drug even within 7 hours. Outcome and hematoma rates were at least as favorable as for trials of therapy with a 3-hour time window. Subgroups with a poor prognosis include low baseline neurological score, baseline CT changes, and proximal ICA thrombosis. However, approximately 30% of patients with each of these characteristics show a good outcome, so their inclusion in future routine rtPA protocols is still justified.
authors.affiliation: Cerebrovascular Unit and Ataxia Research Center, Hôpital Neurologique, Lyon, France.
authors.forename: P
authors.initials: P
authors.lastname: Trouillas
authors.forename: N
authors.initials: N
authors.lastname: Nighoghossian
authors.forename: L
authors.initials: L
authors.lastname: Derex
authors.forename: P
authors.initials: P
authors.lastname: Adeleine
authors.forename: J
authors.initials: J
authors.lastname: Honnorat
authors.forename: P
authors.initials: P
authors.lastname: Neuschwander
authors.forename: G
authors.initials: G
authors.lastname: Riche
authors.forename: J C
authors.initials: JC
authors.lastname: Getenet
authors.forename: W
authors.initials: W
authors.lastname: Li
authors.forename: J C
authors.initials: JC
authors.lastname: Froment
authors.forename: F
authors.initials: F
authors.lastname: Turjman
authors.forename: D
authors.initials: D
authors.lastname: Malicier
authors.forename: G
authors.initials: G
authors.lastname: Fournier
authors.forename: A L
authors.initials: AL
authors.lastname: Gabry
authors.forename: X
authors.initials: X
authors.lastname: Ledoux
authors.forename: Y
authors.initials: Y
authors.lastname: Berthezène
authors.forename: P
authors.initials: P
authors.lastname: Ffrench
authors.forename: M
authors.initials: M
authors.lastname: Dechavanne
mesh_terms: D000328:Adult; D000368:Aged; D002340:Carotid Artery Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D002561:Cerebrovascular Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator